C-peptide: difference between revisions
Diff·revision 4 → 5·03:23, 29 Sep 2024
Difference between revision 4 and revision 5 of C-peptide. 3 lines changed; the page grew by 334 bytes.
| Revision 4 — 20:05, 20 Sep 2024 DEXA_Dilys (talk) alphabetise the see-also list 2,172 bytes +280 | Revision 5 — 03:23, 29 Sep 2024 CategoryBot (talk) bot: sort category members 2,506 bytes +334 | ||
|---|---|---|---|
| 11 | Insulin undergoes variable first-pass hepatic extraction of 40–80%, so peripheral insulin understates secretion by an amount that differs between people and with pulsatility. C-peptide avoids this and is the analyte used in any rigorous assessment of [[Beta cell function|beta-cell function]].{{r|jones2013}} | 11 | Insulin undergoes variable first-pass hepatic extraction of 40–80%, so peripheral insulin understates secretion by an amount that differs between people and with pulsatility. C-peptide avoids this and is the analyte used in any rigorous assessment of [[Beta cell function|beta-cell function]].{{r|jones2013}} |
| 12 | 12 | ||
| + | 13 | Its principal limitation is renal: C-peptide is cleared by the kidney, so concentrations rise in renal impairment independently of secretion, and interpretation in that setting requires care.{{r|ada2024}} | |
| + | 14 | ||
| 13 | == Use in assessment == | 15 | == Use in assessment == |
| 14 | Deconvolution of a peripheral C-peptide profile using known kinetics yields a secretion rate, which is the reference approach for quantifying [[Insulin secretion|insulin secretion]].{{r|rorsman2013}} It requires timed sampling and modelling and is a research technique.{{r|jones2013}} | 16 | Deconvolution of a peripheral C-peptide profile using known kinetics yields a secretion rate, which is the reference approach for quantifying [[Insulin secretion|insulin secretion]].{{r|rorsman2013}} It requires timed sampling and modelling and is a research technique.{{r|jones2013}} |
| ⋮ | ⋮ | ||
| 21 | {{reflist}} | 23 | {{reflist}} |
| 22 | <ref name="jones2013">Jones AG, Hattersley AT. "The clinical utility of C-peptide measurement in the care of patients with diabetes." ''Diabetic Medicine'' 30(7):803–817 (2013). DOI:10.1111/dme.12159. PMID 23413806.</ref> | 24 | <ref name="jones2013">Jones AG, Hattersley AT. "The clinical utility of C-peptide measurement in the care of patients with diabetes." ''Diabetic Medicine'' 30(7):803–817 (2013). DOI:10.1111/dme.12159. PMID 23413806.</ref> |
| + | 25 | <ref name="ada2024">American Diabetes Association. "Standards of Care in Diabetes." ''Diabetes Care'' 47(Suppl 1) (2024).</ref> | |
| 23 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> | 26 | <ref name="rorsman2013">Rorsman P, Braun M. "Regulation of insulin secretion in human pancreatic islets." ''Annual Review of Physiology'' 75:155–179 (2013). PMID 22974438.</ref> |
| 24 | 27 |